Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial.
The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) (NCT02256436)’ (abstract number 4532) was presented at the 2021 ASCO Annual Meeting.
1. What were the 5-year findings of the study in terms of overall response rate and duration of response? (00:21- 02:45)
2. How did the safety profile of pembrolizumab compare with that of chemotherapy over 5 years? (02:45-03:17)
3. What has been the impact of this study on clinical practice? (03:17-04:15)
4. What are your thoughts on NICE’s withdrawn approval for pembrolizumab in patients with platinum-refractory advanced urothelial cancer? (04:15-05:29)
Disclosures: Dr Joaquim Bellmunt is the principle investigator of the KEYNOTE-045 trial and has received fees from Merck to be part of the advisory board.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Bladder Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Robert Jones, ASCO 2022: Maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma – Phase 2 ATLANTIS trial
Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma. Questions: What is the rationale for the use of cabozantinib in the […]
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!